On September 12, 2026, the International Society of Urological Pathology (ISUP) will host a “Multidisciplinary Expert Consultation Conference on Precision Biomarker Testing in Bladder and Prostate Cancer“, open to members and non-member clinicians and scientists in pathology, urology, oncology, and related fields. The conference will take place immediately preceding the 38th European Congress of Pathology (ECP 2026) in Stockholm, Sweden, and will be held in person without a hybrid format.
Meeting Objectives:
Date and Time: September 12, 2026, 7:30 am – 1:30 pm (Stockholm, Sweden)
Meeting Venue: Grand Hôtel Stockholm (Website: https://grandhotel.se/)
Address: Södra Blasieholmshamnen 8, 103 27 Stockholm, Sweden
Agenda: Details coming soon
WG1 Subgroup 1: FGFR – MIBC and NMIBC
Hikmat Al-Ahmadie (Chair), Arndt Hartmann, Jeffrey S. Ross, David J. McConkey, Dilek Ertoy Baydar, Bas WG van Rhijn, Tianxin Lin
WG1 Subgroup 2: HER2 and other/emerging drug antibody conjugates
Charles Guo (Chair), Mahmut Akgul, Adeboye O. Osunkoya, Isabel Alvarado-Cabrero, Ankur Sangoi, Ashish M. Kamat, Joshua J. Meeks
WG1 Subgroup 3: Immune related biomarkers (PD-L1, MMR, TMB and novel/emerging markers)
Markus Eckstein (Chair), Donna E. Hansel, Toyonori Tsuzuki, Puay Hoon Tan, Eva M. Comperat, Michael C. Cookson, Wassim Kassouf
WG1 Subgroup 4: Preanalytical issues
Maria Raspollini (Chair), Maria S. Tretiakova, Sean R. Williamson, Theodorus van der Kwast, Santosh Menon, Büşra Yaprak Bayrak
WG1 Subgroup 5: Liquid biomarkers (blood and urine)
Joshua I. Warrick (Chair), Lars Dyrskjøt, Bishoy M. Faltas, Hui Ying He, Philippe Spiess, Roger Li
WG1 Subgroup 6: Digital/artificial intelligence
Seema Kaushal (Chair), Francesca Khani, George J. Netto, William Y. Kim, David M. Berman, Shahrokh F. Shariat
WG2 Subgroup 1: Preanalytical and postanalytical considerations
WG2 Subgroup 2: BRCA1 and 2 and HRR
Steven C. Smith and Jane Nguyen (Chairs), Jiaoti Huang, Daniel W. Lin, Pasquale Rescigno (oncologist), Mark A. Rubin
WG2 Subgroup 3: MSI-H/dMMR/TMB>10
Nancy Greenland and Rafael Jimenez (Chairs), Daniel M. Berney, Holger Moch, Andrea Necchi ), Sara E. Wobker
WG2 Subgroup 4: PI3KCA-AKT-mTOR pathway inhibitors (PTEN) and other chemotherapy-related predictive biomarkers
Tamara Lotan and James G. Kench (Chairs), Thomas W. Flaig, Gianluca Giannarini, Rajal B. Shah, Jeffrey So
WG2 Subgroup 5: Other potential or emerging tumor-agnostic biomarkers (e.g., ADCs, DLL3, PD-L1)
Aiman Haider and Angelo M. DeMarzo (Chairs), Mahul B. Amin, Anders Bjartell, Arul M. Chinnaiyan, Herbert Lepor, Anandi Lobo, Daniel E. Spratt
WG2 Subgroup 6: Liquid biopsy (e.g., ctDNA, CTCs) and digital/artificial intelligence
Fiona Maclean and Turki Al-Hussain (Chairs), Ni Chen, Michael C. Haffner, Anil V. Parwani, Chin Lee Wu
General questions: Katrina Collins katrinacollinsmd@gmail.com and/or Nancy Greenland nancy.greenland@ucsf.edu
Partially sponsored by: